Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives

Details for Australian Patent Application No. 2007252982 (hide)

Owner Bioalliance Pharma Ecole Normale Superieure De Cachan Centre National de la Recherche Scientifique

Inventors Auclair, Christian; Polard, Valerie; Maksimenko, Andrei

Agent Davies Collison Cave

Pub. Number AU-B-2007252982

PCT Pub. Number WO2007/135538

Priority 06290822.3 22.05.06 EP; 60/838,860 21.08.06 US

Filing date 21 May 2007

Wipo publication date 29 November 2007

Acceptance publication date 23 August 2012

International Classifications

C07D 471/04 Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups

A61K 31/475 - having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine

A61P 35/00 Antineoplastic agents

Event Publications

11 December 2008 PCT application entered the National Phase

  PCT publication WO2007/135538 Priority application(s): WO2007/135538

23 August 2012 Application Accepted

  Published as AU-B-2007252982

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007252986-Progastrin inhibitors in the treatment of colon cancer

2007252967-A composition for inactivating an enveloped virus